Align Technology, Inc. (NASDAQ:ALGN) CFO John Morici sold 1,500 shares of the business’s stock in a transaction that occurred on Friday, November 24th. The shares were sold at an average price of $255.00, for a total transaction of $382,500.00. Following the completion of the sale, the chief financial officer now owns 1,544 shares of the company’s stock, valued at $393,720. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Align Technology, Inc. (NASDAQ ALGN) traded up $5.65 during trading on Wednesday, hitting $233.01. The stock had a trading volume of 1,215,400 shares, compared to its average volume of 1,023,886. Align Technology, Inc. has a one year low of $88.56 and a one year high of $266.41. The company has a market cap of $18,104.13, a PE ratio of 66.81, a P/E/G ratio of 2.16 and a beta of 1.43.
Align Technology (NASDAQ:ALGN) last posted its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.82 by $0.19. Align Technology had a return on equity of 25.60% and a net margin of 19.98%. The business had revenue of $385.30 million for the quarter, compared to analysts’ expectations of $359.80 million. During the same quarter in the prior year, the business earned $0.63 EPS. The firm’s revenue for the quarter was up 38.3% on a year-over-year basis. sell-side analysts expect that Align Technology, Inc. will post 3.62 earnings per share for the current year.
A number of analysts recently weighed in on ALGN shares. Stifel Nicolaus reaffirmed a “buy” rating and issued a $225.00 price objective (up previously from $205.00) on shares of Align Technology in a report on Thursday, October 19th. Robert W. Baird restated a “buy” rating and set a $290.00 price objective on shares of Align Technology in a research report on Wednesday, November 29th. Morgan Stanley upped their price objective on shares of Align Technology from $257.00 to $300.00 and gave the company an “overweight” rating in a research note on Monday, November 27th. Northcoast Research reaffirmed a “buy” rating and set a $230.00 price objective (up from $200.00) on shares of Align Technology in a research note on Tuesday, October 10th. Finally, Credit Suisse Group reaffirmed a “positive” rating and set a $261.00 price objective (up previously from $209.00) on shares of Align Technology in a research report on Thursday, November 9th. Eleven research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average price target of $235.55.
Align Technology Company Profile
Align Technology, Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment.
Receive News & Ratings for Align Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.